Progressive changes in platelet counts and Fib-4 scores precede the diagnosis of advanced fibrosis in NASH patients

Table 2 Characteristics of patients undergoing magnetic resonance elastography

	MRE 0-2.9		MRE 2.9-3.5		MRE 3.5-4		MRE 4-5		MRE 5+
	(% or SD)		(% or SD)		(% or SD)		(% or SD)		(% or SD)
Total (N)	48	(100%)	15	(100%)	6	(100%)	13	(100%)	24	(100%)
Follow-up > 1 yr (N)	42	(88%)	12	(80%)	6	(100%)	10	(77%)	23	(96%)
Follow-up (mean, yr)	9.8	(4.87)	9.4	(4.87)	12.4	(4.87)	10.7	(4.87)	10.6	(4.87)
Age (mean, yr)	57.8	(15.4)	61.6	(13.5)	63.0	(9.0)	61.5	(8.3)	60.6	(13.4)
Sex
Male (N)	17	(35%)	5	(33%)	5	(83%)	6	(46%)	11	(46%)
Female (N)	31	(65%)	10	(67%)	1	(17%)	7	(54%)	13	(54%)
Ethnicity
White (N)	30	(63%)	8	(53%)	4	(67%)	10	(77%)	15	(63%)
African American (N)	2	(4%)	0	(0%)	0	(0%)	0	(0%)	1	(4%)
Hispanic (N)	6	(13)	3	(20)	1	(17)	1	(8)	5	(21)
Asian American (N)	9	(19)	1	(7)	0	(0)	1	(8)	1	(4)
Other (N)	1	(2)	3	(20)	1	(17)	1	(8)	2	(8)
Smoker
Yes (N)	2	(4)	1	(7)	0	(0)	1	(8)	1	(4)
No (N)	28	(58)	11	(73)	6	(100)	5	(38)	12	(50)
Former (N)	18	(38)	3	(20)	0	(0)	7	(54)	11	(46)
Diabetes mellitus
Yes (N)	14	(29)	9	(60)	4	(67)	9	(69)	15	(63)
No (N)	34	(71)	6	(40)	2	(33)	4	(31)	9	(38)
Hypertension
Yes (N)	29	(60)	12	(80)	5	(83)	8	(62)	16	(67)
No (N)	19	(40)	3	(20)	1	(17)	5	(38)	8	(33)
BMI (mean, last)	33	(7)	32	(8)	38	(7)	35	(6)	33	(6)
Laboratory results
SGOT (last, IU/L)	36	(18)	52	(41)	63	(32)	91	(92)	60	(40)
SGPT (last, IU/L)	48	(29)	57	(48)	79	(34)	101	(88)	59	(43)
Platelets (last, 1000/mL)	244	(60)	231	(62)	205	(39)	201	(74)	182	(75)
Fib-4 score (last)	1.4	(0.9)	1.8	(1.0)	2.6	(1.5)	2.6	(1.1)	3.5	(2.0)
MRE fibrosis score (mean)	2.5	(0.3)	3.2	(0.2)	3.7	(0.1)	4.3	(0.2)	8.2	(3.5)
Correlation-plts (mean)	-0.06	(0.43)	-0.06	(0.43)	-0.28	(0.45)	-0.44	(0.33)	-0.64	(0.35)
Correlation-Fib-4 (mean)	0.44	(0.43)	0.44	(0.43)	0.66	(0.19)	0.61	(0.35)	0.68	(0.32)

BMI: Body mass index; MRE: Magnetic resonance elastography; SGOT: Serum glutamic oxalacetic transaminase; SGPT: Serum glutamic-pyruvic transaminase.